隐含的ADR入院:一项队列研究引入了一种新的行政数据方法,用于识别与药物相关的住院治疗
Miriam Schechner1, Marietta Rottenkolber1, Clara Weglage1
1Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Nußbaumstr. 5, 80336 Munich, Germany.
Drug safety
|September 16, 2025
概括
一种新的方法,暗示药物不良反应-入院,改善了检测与药物相关的住院治疗在多药患者. 这种可扩展的方法通过将药物暴露与行政数据中的不良事件联系起来来增强药物监管.
科学领域:
- 药监和药物安全 药监和药物安全
- 医疗信息学 医疗信息学
- 流行病学 流行病学
背景情况:
- 药物不良反应 (ADR) 是不计划住院的主要原因,特别是在多药患者中.
- 传统的ADR检测方法缺乏可扩展性和灵敏性.
研究的目的:
- 介绍和评估一种新的,可扩展的方法,称为隐含的ADR-admissions.
- 通过使用行政数据,提高可信的药物相关住院病例的检测.
主要方法:
- 对123,662名年龄≥40岁且使用多种药物的人进行了回顾性队列研究.
- 隐含的ADR入院被定义为在90天内与药物暴露相关的15次不良事件的住院治疗.
- 与不良事件入院,明确的ADR入院和可预防的ADR入院的发生率的比较.
主要成果:
- 默认的ADR-admissions发生在2.6%的患者中,明显高于明确的ADR-admissions (0.4%).
- 对胃肠道出血的暗示ADR入院的发生率是可预防ADR入院的20倍.
- 与低脑血症相关的住院治疗和不适当药物的使用预测暗示ADR入院.
结论:
- 隐含的ADR入院方法为检测与药物有关的住院治疗提供了更好的特异性和灵敏性.
- 这种方法提供了一个可扩展的,自动化工具,用于药监.
- 在药物安全监测的常规实施之前,需要进一步验证.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
319
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
319
Analysis of Population Pharmacokinetic Data
682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Drug Dosing: Geriatric Patients
228
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
228
Dosage Regimens: Designs and Approaches
266
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
266
Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155


